Clinical evidence deficiencies drive CHMP negative opinions and pre-opinion withdrawals in the EU centralized...

Market authorization applications that do not obtain authorization after CHMP review, whether through a formal negative opinion or pre-opinion withdrawal, remain poorly characterized at a systems level, despite substantial strategic, and commercial implications for applicants, and the broader impact on public-health.

We conducted a retrospective descriptive analysis of 47 Article 8[3] new marketing authorization applications (MAAs) evaluated by the CHMP between 2021 and 2025, comprising 16 applications with a formal negative CHMP opinion and 31 withdrawn applications with an underlying negative benefit-risk assessment. Public assessment documents were reviewed, and documented CHMP concerns were scored across four predefined domains: CMC, non-clinical, clinical, and regulatory/procedural, including subsequent secondary sub-categorization to allow for more detail. Procedural timelines, re-examination outcomes, and multi-domain co-occurrence patterns were also summarized. Findings were summarized descriptively using counts, percentages, and procedural-duration comparisons.

Withdrawn and refused MAAs showed comparable product profiles and similar rates of orphan designation. Withdrawals occurred throughout all phases of the assessment procedure, reflecting different points at which applicants considered continuation no longer viable. Across both cohorts, procedural timelines frequently exceeded theoretical EMA benchmarks, with the excess concentrated in clock-stop phases. Clinical concerns were the most frequently documented domain, observed in 16/16 refused applications (100%) and 28/31 withdrawals (90%). Within the clinical domain, the secondary categories study-design concerns and insufficient evidence of efficacy were the most common findings and frequently co-occurred. Compared with refusals, withdrawals showed a broader deficiency profile, more often involving multiple domains, particularly CMC and regulatory/procedural concerns in addition to clinical deficiencies.

These observations suggest that unsuccessful outcomes in this cohort were commonly associated with limitations in evidence generation, dossier readiness, and alignment between regulatory pathway and evidence maturity. Earlier cross-domain readiness assessment may help applicants identify major unresolved deficiencies before or during CHMP review.